Side-by-side · Research reference
Kisspeptin-10vsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED10/41 cited
BFDA-ApprovedFlagship15/53 cited
Kisspeptin-10
Neuropeptide · GPR54 Agonist
Phase 1/2Clinical stage
IV / SQ · Investigational
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Kisspeptin-10
Semaglutide
Primary target
GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026Collado-Sole 2026
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026Rønnekleiv 2026
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026Rønnekleiv 2026
Glucose-dependent insulin release preserves physiological feedback
Origin
C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
Kisspeptin-10
Semaglutide
Clinical trial dose
Phase 1/2 investigational
Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).
—
Route
IV or SQ administration
IV preferred in controlled trials for precise pulsatile delivery.
—
Evidence basis
Phase 1/2 trials
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Half-life
Short (minutes)
Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.
~7 days (168 h)WEGOVY (semaglutide) injection 2021
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Frequency
—
Once weekly, same day each week
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
04Side Effects & Safety
Parameter
Kisspeptin-10
Semaglutide
Ovarian hyperstimulation
Theoretical risk with supraphysiological dosing in fertility protocols
—
Headache
Mild, reported in early-phase trials
—
Nausea
Transient GI symptoms with IV bolus
—
Hot flashes
Vasomotor symptoms from LH surge
—
Injection site reaction
Erythema, mild discomfort (SQ route)
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
Kisspeptin-10
- ·Active pregnancy
- ·Hormone-sensitive malignancy (breast, ovarian, endometrial)
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Kisspeptin-10
- ·Polycystic ovary syndrome (PCOS) without monitoring
- ·Uncontrolled thyroid dysfunction
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Kisspeptin-10
Semaglutide
1. Reconstitution (if lyophilized)
Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Route selection
IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Monitoring
Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Storage
Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
Kisspeptin-10
— no documented stacks
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)